 Your new post is loading...
Scoop.it!
Sun Life Financial Inc. is poised to raise its dividend for the first time since the financial crisis and repurchase more than $200-million of its stock, says Peter Routledge, analyst at National Bank Financial. Source “Sun Life possesses two... 
No comment yet.
Sign up to comment
Scoop.it!
Editor's Note: The following post comes to us from Covington & Burling LLP and is based on a Covington article by Jack Bodner, Leonard Chazen, and Donald Ross. This post is part of the Delaware...
Scoop.it!
In the Another View column, Bill George examines four situations — Amgen, PepsiCo, DuPont, and Allergan — to see where activist investors have it wrong.
Scoop.it!
Corporations Brace for a Rise in Shareholder Activists
Scoop.it!
Hedge funds that agitate for corporate change have had a good run, with wins against GM, Family Dollar and others. But prominent losses show they have no magic formula.
Scoop.it!
Editor's Note: Luis A. Aguilar is a Commissioner at the U.S. Securities and Exchange Commission. This post is based on Commissioner Aguilar’s public statement at a recent meeting of the SEC Advisor...
Scoop.it!
Bill George is a professor of management practice at Harvard Business School, where he has taught leadership since 2004. He is the former CEO of Medtronic and a Best-Selling Author.
Scoop.it!
Watch the video Beware! Activist investors are winning on Yahoo Finance . Charles Jacobs, partner at Linklaters, discusses the role of the activist shareholder following news that General Motors had agreed to a $5-billion stock buyback to end a standoff with an activist investor.
Scoop.it!
LONDON (Reuters) - Hedge funds recorded their best monthly performance for a year in February, driven by rising equity markets and led by a 5.37 percent gain for activist funds, data from industry tracker
Scoop.it!
The fall in the euro accelerated and bond yields in the eurozone hit fresh lows, showing how the effects of the European Central Bank’s bond-buying program continue to grip the region’s markets.
Scoop.it!
Editor's Note: John Gould is senior vice president at Cornerstone Research. This post discusses a Cornerstone Research report by Olga Koumrian, titled “Shareholder Litigation Involving Acquisitions...
Scoop.it!
Proxy access has emerged as the dominant issue, and one of the most contentious, so far this corporate annual meeting season, taking the air out of a lot of other typically high-profile proposals.
|
Scoop.it!
A new law in Germany highlighted the slow progress of American companies in placing women on corporate boards.
Scoop.it!
You’ve read about them in the news lately. You’ve read about how much leverage they exert on companies’ CEOs. You’ve read about the astonishing sums they manage to get in share buybacks and dividend hikes.
Scoop.it!
PARIS (Reuters) - Activist funds are running out of patience with European companies which carry on building warchests with no clear spending strategy in place.The funds - which take a stake in a firm
Scoop.it!
Activist investors, such as Bill Ackman, are famous for the huge profits they make from their active investment by changing how companies are managed.
Scoop.it!
Nearly one year after hedge fund billionaire Bill Ackman stepped onto a New York City stage to announce an allegiance with Valeant Pharmaceuticals, his Pershing Square hedge fund finally owns shares of the company. Ackman’s hedge fund owns a nearly a 5% stake in Valeant, Reuters first reported on Monday. It's [...]
Scoop.it!
Shareholders In The United Kingdom Paul L. Davies University of Oxford- Faculty of Law European Corporate Governance Institute (ECGI) - Law Working Paper No. 280/2015 Abstract: This paper, a version o
Scoop.it!
Harry Wilson and his hedge fund backers won a $5 billion concession from General Motors. But some worry the cost is too high.
Scoop.it!
TORONTO, March 10 (Reuters) - Ontario's Liberal governmentis crafting a plan to sell shares in provincially ownedelectrical utility Hydro One, the Globe and Mail reported onTuesday.The story, which
Scoop.it!
Hedge fund mogul William Ackman has purchased a $3.3 billion stake in Valeant Pharmaceuticals International, making his firm the drug company's fifth-largest stakeholder, a source familiar with the matter said on Monday.
Scoop.it!
Editor's Note: Trevor Norwitz is a partner in the Corporate Department at Wachtell, Lipton, Rosen & Katz and Lecturer in Law at Columbia Law School. This post is part of the Delaware law series...
Scoop.it!
Editor's Note: Brian Cheffins is Professor of Corporate Law at the University of Cambridge. The following post is based on an article co-authored by Professor Cheffins, David Chambers of Cambridge ...
|
